药物用于宁抑制的重新定位:确定用于高血压管理的泛尼诺斯塔特
Nisha Bansal1,2, Mohammad Khalid Parvez3, M Arockia Babu4
1Gramothan Vidyapeeth Home Science Girls PG College, Sangaria, Rajasthan, India. bansalnisha314@gmail.com.
Molecular diversity
|June 23, 2025
概括
研究人员重新使用FDA批准的药物,以找到新的高血压宁抑制剂. 帕诺比诺斯塔特成为潜在的头,在抑制血压调节中的关键酶宁方面表现有前途.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 氨酸是氨酸- ангиотензин- алдостерон系统 (RAAS) 中的一个关键酶,调节血压.
- 目前用于高血压的胺抑制剂具有局限性,包括适度的疗效和副作用,如高胆固醇血和功能障碍.
- 对新型,有效的宁抑制剂有着未满足的需求.
研究的目的:
- 通过对美国FDA批准的小分子进行药物重新定位来识别新型宁抑制剂.
- 通过基于结构的虚拟查和实验分析来评估帕诺比诺斯塔特作为潜在的类宁抑制剂.
主要方法:
- 1880年的基于结构的虚拟查 (SBVS) 美国FDA批准的药物.
- 分子对接,动力学和力学研究,以支持SBVS.
- 在体外酶抑制试验 (基于ELISA) 来确定IC50值.
主要成果:
- 帕诺比诺斯塔特被确定为一种潜在的类宁抑制剂.
- 帕诺比诺斯塔特在体外表现出宁抑制,其IC50为201.27nM.
- 这种功效与临床宁抑制剂阿利斯基伦 (IC50 162.22 nM) 相当.
结论:
- 作为HDAC抑制剂的帕诺比诺斯塔特显示出其作为双重作用药物的潜力,用于管理高血压.
- 这些发现支持HDACs在调节RAAS和心血管功能的作用.
- 药物重新定位是发现新型治疗剂的可行策略.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
911
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
911
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
949
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
949
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263